Chromogenix, One-Stage Clotting Assays OK With Genetics Institute ReFacto
This article was originally published in The Gray Sheet
Clinicians may use either a one-stage clotting assay or a chromogenic substrate assay with Genetics Institute's ReFacto provided that the dose of the recombinant Factor VIII product is adjusted to reflect the lower results obtained with the former, FDA's Blood Products Advisory Committee agreed at its Dec. 11 meeting.
You may also be interested in...
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.
US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says
Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.